Biotech’s 2026 IPOs deliver broad gains through August

Biotech’s 2026 IPO class has delivered strong returns, with 18 of 21 companies trading above their offering prices as of Sept. 1 and 13 gaining more than 30%. The median gain was 36%, while the average was 48%, according to BioCentury’s analysis of biotechs listing on NASDAQ this year.

The performance comes alongside a recovery in issuance: The 21 biotech IPOs through Sept. 1 compare with 14 in all of 2025...